ID   WIPF1_HUMAN             Reviewed;         503 AA.
AC   O43516; B8ZZM1; D3DPE4; Q15220; Q53TA9; Q6MZU9; Q9BU37; Q9UNP1;
DT   21-FEB-2001, integrated into UniProtKB/Swiss-Prot.
DT   30-NOV-2010, sequence version 3.
DT   18-JUN-2025, entry version 214.
DE   RecName: Full=WAS/WASL-interacting protein family member 1;
DE   AltName: Full=Protein PRPL-2;
DE   AltName: Full=Wiskott-Aldrich syndrome protein-interacting protein;
DE            Short=WASP-interacting protein;
GN   Name=WIPF1; Synonyms=WASPIP, WIP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANTS LEU-198 AND GLY-495,
RP   FUNCTION, TISSUE SPECIFICITY, AND INTERACTION WITH WASP; PROFILIN AND
RP   ACTIN.
RX   PubMed=9405671; DOI=10.1073/pnas.94.26.14671;
RA   Ramesh N., Anton I.M., Hartwig J.H., Geha R.S.;
RT   "WIP, a protein associated with Wiskott-Aldrich syndrome protein, induces
RT   actin polymerization and redistribution in lymphoid cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:14671-14676(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANTS LEU-198 AND GLY-495.
RC   TISSUE=Tonsil;
RA   Kreideweiss S., Delany-Heiken P., Nordheim A., Ruhlmann A.;
RL   Submitted (JAN-1998) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANT LEU-198.
RC   TISSUE=Endometrial tumor;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT LEU-198.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4), AND VARIANT LEU-198.
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 192-503 (ISOFORM 1), INTERACTION WITH WASP,
RP   AND VARIANT LEU-198.
RX   PubMed=10202051;
RA   Stewart D.M., Tian L., Nelson D.L.;
RT   "Mutations that cause the Wiskott-Aldrich syndrome impair the interaction
RT   of Wiskott-Aldrich syndrome protein (WASP) with WASP interacting protein.";
RL   J. Immunol. 162:5019-5024(1999).
RN   [8]
RP   FUNCTION.
RX   PubMed=10878810; DOI=10.1038/35017080;
RA   Moreau V., Frischknecht F., Reckmann I., Vincentelli R., Rabut G.,
RA   Stewart D.M., Way M.;
RT   "A complex of N-WASP and WIP integrates signalling cascades that lead to
RT   actin polymerization.";
RL   Nat. Cell Biol. 2:441-448(2000).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=T-cell;
RX   PubMed=19367720; DOI=10.1021/pr800500r;
RA   Carrascal M., Ovelleiro D., Casas V., Gay M., Abian J.;
RT   "Phosphorylation analysis of primary human T lymphocytes using sequential
RT   IMAC and titanium oxide enrichment.";
RL   J. Proteome Res. 7:5167-5176(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-345 AND SER-350, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   INTERACTION WITH FNBP1L.
RX   PubMed=19798448; DOI=10.1371/journal.pgen.1000675;
RA   Giuliani C., Troglio F., Bai Z., Patel F.B., Zucconi A., Malabarba M.G.,
RA   Disanza A., Stradal T.B., Cassata G., Confalonieri S., Hardin J.D.,
RA   Soto M.C., Grant B.D., Scita G.;
RT   "Requirements for F-BAR proteins TOCA-1 and TOCA-2 in actin dynamics and
RT   membrane trafficking during Caenorhabditis elegans oocyte growth and
RT   embryonic epidermal morphogenesis.";
RL   PLoS Genet. 5:E1000675-E1000675(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-350, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH DBNL.
RX   PubMed=19910490; DOI=10.1091/mbc.e09-02-0106;
RA   Cortesio C.L., Perrin B.J., Bennin D.A., Huttenlocher A.;
RT   "Actin-binding protein-1 interacts with WASp-interacting protein to
RT   regulate growth factor-induced dorsal ruffle formation.";
RL   Mol. Biol. Cell 21:186-197(2010).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-340; THR-345 AND SER-350, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   INVOLVEMENT IN WAS2.
RX   PubMed=22231303; DOI=10.1084/jem.20110896;
RA   Lanzi G., Moratto D., Vairo D., Masneri S., Delmonte O., Paganini T.,
RA   Parolini S., Tabellini G., Mazza C., Savoldi G., Montin D., Martino S.,
RA   Tovo P., Pessach I.M., Massaad M.J., Ramesh N., Porta F., Plebani A.,
RA   Notarangelo L.D., Geha R.S., Giliani S.;
RT   "A novel primary human immunodeficiency due to deficiency in the WASP-
RT   interacting protein WIP.";
RL   J. Exp. Med. 209:29-34(2012).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-234; SER-340 AND SER-350, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-340, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 29-60 IN COMPLEX WITH ACTIN.
RX   PubMed=16275905; DOI=10.1073/pnas.0507021102;
RA   Chereau D., Kerff F., Graceffa P., Grabarek Z., Langsetmo K., Dominguez R.;
RT   "Actin-bound structures of Wiskott-Aldrich syndrome protein (WASP)-homology
RT   domain 2 and the implications for filament assembly.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:16644-16649(2005).
CC   -!- FUNCTION: Plays a role in the reorganization of the actin cytoskeleton.
CC       Contributes with NCK1 and GRB2 in the recruitment and activation of
CC       WASL. May participate in regulating the subcellular localization of
CC       WASL, resulting in the disassembly of stress fibers in favor of
CC       filopodia formation. Plays a role in the formation of cell ruffles (By
CC       similarity). Plays an important role in the intracellular motility of
CC       vaccinia virus by functioning as an adapter for recruiting WASL to
CC       vaccinia virus. {ECO:0000250, ECO:0000269|PubMed:10878810,
CC       ECO:0000269|PubMed:19910490, ECO:0000269|PubMed:9405671}.
CC   -!- SUBUNIT: Binds to WAS, profilin and actin. Binds to WASL (By
CC       similarity). Interacts with DBNL. Interacts with FNBP1L (via the SH3
CC       domain) (PubMed:19798448). {ECO:0000250, ECO:0000269|PubMed:10202051,
CC       ECO:0000269|PubMed:16275905, ECO:0000269|PubMed:19798448,
CC       ECO:0000269|PubMed:19910490, ECO:0000269|PubMed:9405671}.
CC   -!- INTERACTION:
CC       O43516; Q9NYB9: ABI2; NbExp=4; IntAct=EBI-346356, EBI-743598;
CC       O43516; P13196: ALAS1; NbExp=3; IntAct=EBI-346356, EBI-3905054;
CC       O43516; Q14296: FASTK; NbExp=3; IntAct=EBI-346356, EBI-1754067;
CC       O43516; P62993: GRB2; NbExp=5; IntAct=EBI-346356, EBI-401755;
CC       O43516; P08631: HCK; NbExp=3; IntAct=EBI-346356, EBI-346340;
CC       O43516; P14317: HCLS1; NbExp=2; IntAct=EBI-346356, EBI-750369;
CC       O43516; Q9NSC5: HOMER3; NbExp=3; IntAct=EBI-346356, EBI-748420;
CC       O43516; Q9GZQ8: MAP1LC3B; NbExp=4; IntAct=EBI-346356, EBI-373144;
CC       O43516; P16333: NCK1; NbExp=3; IntAct=EBI-346356, EBI-389883;
CC       O43516; P53992: SEC24C; NbExp=3; IntAct=EBI-346356, EBI-81134;
CC       O43516; P42768: WAS; NbExp=25; IntAct=EBI-346356, EBI-346375;
CC       O43516; O00401: WASL; NbExp=10; IntAct=EBI-346356, EBI-957615;
CC       O43516; O00308: WWP2; NbExp=4; IntAct=EBI-346356, EBI-743923;
CC       O43516; Q60598: Cttn; Xeno; NbExp=4; IntAct=EBI-346356, EBI-397955;
CC       O43516-4; Q9NYB9-2: ABI2; NbExp=3; IntAct=EBI-12052927, EBI-11096309;
CC       O43516-4; Q9Y698: CACNG2; NbExp=3; IntAct=EBI-12052927, EBI-6659211;
CC       O43516-4; O43639: NCK2; NbExp=3; IntAct=EBI-12052927, EBI-713635;
CC       O43516-4; O15258: RER1; NbExp=3; IntAct=EBI-12052927, EBI-716910;
CC       O43516-4; P42768: WAS; NbExp=3; IntAct=EBI-12052927, EBI-346375;
CC   -!- SUBCELLULAR LOCATION: Cytoplasmic vesicle {ECO:0000250}. Cytoplasm,
CC       cytoskeleton {ECO:0000250}. Cell projection, ruffle
CC       {ECO:0000269|PubMed:19910490}. Note=Vesicle surfaces and along actin
CC       tails. Colocalizes with actin stress fibers. When coexpressed with
CC       WASL, no longer associated with actin filaments but accumulated in
CC       perinuclear and cortical areas like WASL (By similarity).
CC       {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=O43516-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O43516-2; Sequence=VSP_012965;
CC       Name=3;
CC         IsoId=O43516-3; Sequence=VSP_012966;
CC       Name=4;
CC         IsoId=O43516-4; Sequence=VSP_012964;
CC   -!- TISSUE SPECIFICITY: Highly expressed in peripheral blood mononuclear
CC       cells, spleen, placenta, small intestine, colon and thymus. Lower
CC       expression in ovary, heart, brain, lung, liver, skeletal muscle,
CC       kidney, pancreas, prostate and testis. {ECO:0000269|PubMed:9405671}.
CC   -!- DOMAIN: Binds to WAS within the N-terminal region 170, at a site
CC       distinct from the CDC42-binding site.
CC   -!- DISEASE: Wiskott-Aldrich syndrome 2 (WAS2) [MIM:614493]: An
CC       immunodeficiency disorder characterized by eczema, thrombocytopenia,
CC       recurrent infections, defective T-cell proliferation, and impaired
CC       natural killer cell function. {ECO:0000269|PubMed:22231303}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- MISCELLANEOUS: Recruited to PIP5K-induced vesicle surfaces in the
CC       absence of functional WASL. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the verprolin family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC03767.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=CAA60014.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF031588; AAC03767.1; ALT_FRAME; mRNA.
DR   EMBL; X86019; CAA60014.1; ALT_FRAME; mRNA.
DR   EMBL; BX640870; CAE45928.1; -; mRNA.
DR   EMBL; AC010894; AAY14708.1; -; Genomic_DNA.
DR   EMBL; AC104595; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471058; EAX11131.1; -; Genomic_DNA.
DR   EMBL; CH471058; EAX11132.1; -; Genomic_DNA.
DR   EMBL; CH471058; EAX11133.1; -; Genomic_DNA.
DR   EMBL; BC002914; AAH02914.1; -; mRNA.
DR   EMBL; AF106062; AAD45972.1; -; mRNA.
DR   CCDS; CCDS2260.1; -. [O43516-1]
DR   CCDS; CCDS92901.1; -. [O43516-3]
DR   RefSeq; NP_001070737.1; NM_001077269.1. [O43516-1]
DR   RefSeq; NP_001362761.1; NM_001375832.1. [O43516-1]
DR   RefSeq; NP_001362762.1; NM_001375833.1. [O43516-1]
DR   RefSeq; NP_001362763.1; NM_001375834.1. [O43516-1]
DR   RefSeq; NP_001362764.1; NM_001375835.1. [O43516-3]
DR   RefSeq; NP_003378.3; NM_003387.4. [O43516-1]
DR   RefSeq; XP_011510082.1; XM_011511780.2.
DR   RefSeq; XP_047301705.1; XM_047445749.1. [O43516-1]
DR   RefSeq; XP_047301706.1; XM_047445750.1. [O43516-1]
DR   RefSeq; XP_047301707.1; XM_047445751.1. [O43516-1]
DR   RefSeq; XP_047301708.1; XM_047445752.1. [O43516-1]
DR   RefSeq; XP_047301709.1; XM_047445753.1. [O43516-1]
DR   RefSeq; XP_047301710.1; XM_047445754.1. [O43516-1]
DR   RefSeq; XP_047301711.1; XM_047445755.1. [O43516-1]
DR   RefSeq; XP_047301712.1; XM_047445756.1. [O43516-1]
DR   RefSeq; XP_047301713.1; XM_047445757.1. [O43516-1]
DR   PDB; 2A41; X-ray; 2.60 A; C=29-60.
DR   PDB; 9EZN; NMR; -; B=165-183.
DR   PDB; 9EZO; NMR; -; B=165-183.
DR   PDB; 9EZP; NMR; -; B=165-183.
DR   PDBsum; 2A41; -.
DR   PDBsum; 9EZN; -.
DR   PDBsum; 9EZO; -.
DR   PDBsum; 9EZP; -.
DR   AlphaFoldDB; O43516; -.
DR   SMR; O43516; -.
DR   BioGRID; 113295; 42.
DR   CORUM; O43516; -.
DR   DIP; DIP-17015N; -.
DR   ELM; O43516; -.
DR   FunCoup; O43516; 652.
DR   IntAct; O43516; 28.
DR   MINT; O43516; -.
DR   STRING; 9606.ENSP00000376330; -.
DR   GlyCosmos; O43516; 1 site, 1 glycan.
DR   GlyGen; O43516; 5 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (2 sites).
DR   iPTMnet; O43516; -.
DR   PhosphoSitePlus; O43516; -.
DR   BioMuta; WIPF1; -.
DR   jPOST; O43516; -.
DR   MassIVE; O43516; -.
DR   PaxDb; 9606-ENSP00000376330; -.
DR   PeptideAtlas; O43516; -.
DR   ProteomicsDB; 49004; -. [O43516-1]
DR   ProteomicsDB; 49005; -. [O43516-2]
DR   ProteomicsDB; 49006; -. [O43516-3]
DR   ProteomicsDB; 49007; -. [O43516-4]
DR   Pumba; O43516; -.
DR   Antibodypedia; 4053; 161 antibodies from 33 providers.
DR   DNASU; 7456; -.
DR   Ensembl; ENST00000272746.9; ENSP00000272746.5; ENSG00000115935.19. [O43516-3]
DR   Ensembl; ENST00000359761.7; ENSP00000352802.3; ENSG00000115935.19. [O43516-1]
DR   Ensembl; ENST00000392546.6; ENSP00000376329.2; ENSG00000115935.19. [O43516-1]
DR   Ensembl; ENST00000392547.6; ENSP00000376330.2; ENSG00000115935.19. [O43516-1]
DR   Ensembl; ENST00000409891.5; ENSP00000386431.1; ENSG00000115935.19. [O43516-2]
DR   Ensembl; ENST00000436221.2; ENSP00000388454.2; ENSG00000115935.19. [O43516-1]
DR   Ensembl; ENST00000679041.1; ENSP00000503603.1; ENSG00000115935.19. [O43516-1]
DR   Ensembl; ENST00000698668.1; ENSP00000513869.1; ENSG00000115935.19. [O43516-1]
DR   Ensembl; ENST00000698701.1; ENSP00000513882.1; ENSG00000115935.19. [O43516-1]
DR   GeneID; 7456; -.
DR   KEGG; hsa:7456; -.
DR   MANE-Select; ENST00000679041.1; ENSP00000503603.1; NM_001375834.1; NP_001362763.1.
DR   UCSC; uc002uiz.4; human. [O43516-1]
DR   AGR; HGNC:12736; -.
DR   CTD; 7456; -.
DR   DisGeNET; 7456; -.
DR   GeneCards; WIPF1; -.
DR   HGNC; HGNC:12736; WIPF1.
DR   HPA; ENSG00000115935; Tissue enhanced (lymphoid).
DR   MalaCards; WIPF1; -.
DR   MIM; 602357; gene.
DR   MIM; 614493; phenotype.
DR   OpenTargets; ENSG00000115935; -.
DR   Orphanet; 906; Wiskott-Aldrich syndrome.
DR   VEuPathDB; HostDB:ENSG00000115935; -.
DR   eggNOG; KOG4462; Eukaryota.
DR   GeneTree; ENSGT00910000144296; -.
DR   HOGENOM; CLU_041032_0_0_1; -.
DR   InParanoid; O43516; -.
DR   OMA; NAFGHSQ; -.
DR   OrthoDB; 6157464at2759; -.
DR   PAN-GO; O43516; 2 GO annotations based on evolutionary models.
DR   PhylomeDB; O43516; -.
DR   PathwayCommons; O43516; -.
DR   Reactome; R-HSA-2029482; Regulation of actin dynamics for phagocytic cup formation.
DR   Reactome; R-HSA-5663213; RHO GTPases Activate WASPs and WAVEs.
DR   Reactome; R-HSA-9013148; CDC42 GTPase cycle.
DR   Reactome; R-HSA-9013149; RAC1 GTPase cycle.
DR   Reactome; R-HSA-9664422; FCGR3A-mediated phagocytosis.
DR   SignaLink; O43516; -.
DR   SIGNOR; O43516; -.
DR   BioGRID-ORCS; 7456; 28 hits in 1156 CRISPR screens.
DR   ChiTaRS; WIPF1; human.
DR   EvolutionaryTrace; O43516; -.
DR   GeneWiki; WIPF1; -.
DR   GenomeRNAi; 7456; -.
DR   Pharos; O43516; Tbio.
DR   PRO; PR:O43516; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; O43516; protein.
DR   Bgee; ENSG00000115935; Expressed in blood and 202 other cell types or tissues.
DR   ExpressionAtlas; O43516; baseline and differential.
DR   GO; GO:0015629; C:actin cytoskeleton; TAS:ProtInc.
DR   GO; GO:0005884; C:actin filament; IBA:GO_Central.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IEA:UniProtKB-KW.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0001726; C:ruffle; IEA:UniProtKB-SubCell.
DR   GO; GO:0003779; F:actin binding; TAS:ProtInc.
DR   GO; GO:0008093; F:cytoskeletal anchor activity; IDA:GO_Central.
DR   GO; GO:0005522; F:profilin binding; TAS:ProtInc.
DR   GO; GO:0044183; F:protein folding chaperone; EXP:DisProt.
DR   GO; GO:0017124; F:SH3 domain binding; IPI:UniProtKB.
DR   GO; GO:0030048; P:actin filament-based movement; IBA:GO_Central.
DR   GO; GO:0008154; P:actin polymerization or depolymerization; TAS:ProtInc.
DR   GO; GO:0065003; P:protein-containing complex assembly; TAS:ProtInc.
DR   GO; GO:0051707; P:response to other organism; IEA:Ensembl.
DR   CDD; cd22076; WH2_WAS_WASL-1; 1.
DR   DisProt; DP01172; -.
DR   FunFam; 2.30.29.30:FF:000294; WAS/WASL-interacting protein family member 1; 1.
DR   Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1.
DR   IDEAL; IID00258; -.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR053099; WAS/WASL-interacting_domain.
DR   InterPro; IPR003124; WH2_dom.
DR   PANTHER; PTHR48226; OS06G0326200 PROTEIN; 1.
DR   PANTHER; PTHR48226:SF1; WAS_WASL-INTERACTING PROTEIN FAMILY MEMBER 1; 1.
DR   Pfam; PF02205; WH2; 1.
DR   SMART; SM00246; WH2; 1.
DR   PROSITE; PS51082; WH2; 1.
DR   neXtProt; NX_O43516; -.
DR   PharmGKB; PA162409189; -.
DR   TreeFam; TF332135; -.
PE   1: Evidence at protein level;
KW   3D-structure; Actin-binding; Alternative splicing; Cell projection;
KW   Cytoplasm; Cytoplasmic vesicle; Cytoskeleton; Methylation; Phosphoprotein;
KW   Proteomics identification; Reference proteome; Repeat.
FT   CHAIN           1..503
FT                   /note="WAS/WASL-interacting protein family member 1"
FT                   /id="PRO_0000065941"
FT   DOMAIN          32..49
FT                   /note="WH2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00406"
FT   REPEAT          352..361
FT                   /note="XRSGPXPPXP motif 1"
FT   REPEAT          374..383
FT                   /note="XRSGPXPPXP motif 2"
FT   REPEAT          410..419
FT                   /note="XRSGPXPPXP motif 3"
FT   REGION          1..503
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          45..48
FT                   /note="Binds actin"
FT   COMPBIAS        1..14
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        21..31
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        65..104
FT                   /note="Gly residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        121..137
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        141..154
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        161..174
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        182..191
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        204..223
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        238..247
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        282..298
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        306..323
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        346..371
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        413..434
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        480..494
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         33
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K1I7"
FT   MOD_RES         125
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K1I7"
FT   MOD_RES         134
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K1I7"
FT   MOD_RES         142
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K1I7"
FT   MOD_RES         234
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         340
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         345
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         350
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         220..364
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_012964"
FT   VAR_SEQ         487..503
FT                   /note="GSNRRERGAPPLPPIPR -> EYFCQGF (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.2"
FT                   /id="VSP_012965"
FT   VAR_SEQ         503
FT                   /note="R -> RPPKQAAE (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:17974005"
FT                   /id="VSP_012966"
FT   VARIANT         198
FT                   /note="P -> L (in dbSNP:rs4972450)"
FT                   /evidence="ECO:0000269|PubMed:10202051,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:17974005,
FT                   ECO:0000269|PubMed:9405671, ECO:0000269|Ref.2,
FT                   ECO:0000269|Ref.5"
FT                   /id="VAR_046526"
FT   VARIANT         495
FT                   /note="A -> G"
FT                   /evidence="ECO:0000269|PubMed:9405671, ECO:0000269|Ref.2"
FT                   /id="VAR_010295"
FT   CONFLICT        119
FT                   /note="N -> D (in Ref. 3; CAE45928)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        120
FT                   /note="D -> H (in Ref. 6; AAH02914)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        360
FT                   /note="P -> PV (in Ref. 2; CAA60014)"
FT                   /evidence="ECO:0000305"
FT   HELIX           33..42
FT                   /evidence="ECO:0007829|PDB:2A41"
SQ   SEQUENCE   503 AA;  51258 MW;  09B7A95E6808A46D CRC64;
     MPVPPPPAPP PPPTFALANT EKPTLNKTEQ AGRNALLSDI SKGKKLKKTV TNDRSAPILD
     KPKGAGAGGG GGGFGGGGGF GGGGGGGGGG SFGGGGPPGL GGLFQAGMPK LRSTANRDND
     SGGSRPPLLP PGGRSTSAKP FSPPSGPGRF PVPSPGHRSG PPEPQRNRMP PPRPDVGSKP
     DSIPPPVPST PRPIQSSPHN RGSPPVPGGP RQPSPGPTPP PFPGNRGTAL GGGSIRQSPL
     SSSSPFSNRP PLPPTPSRAL DDKPPPPPPP VGNRPSIHRE AVPPPPPQNN KPPVPSTPRP
     SASSQAPPPP PPPSRPGPPP LPPSSSGNDE TPRLPQRNLS LSSSTPPLPS PGRSGPLPPP
     PSERPPPPVR DPPGRSGPLP PPPPVSRNGS TSRALPATPQ LPSRSGVDSP RSGPRPPLPP
     DRPSAGAPPP PPPSTSIRNG FQDSPCEDEW ESRFYFHPIS DLPPPEPYVQ TTKSYPSKLA
     RNESRSGSNR RERGAPPLPP IPR
//
